Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.

Shi, Yin; Pei, Rui; Liu, Shao

Shi, Yin; Pei, Rui; Liu, Shao.

Afiliación

Shi Y; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Pei R; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Liu S; The Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, China.

Front Oncol ; 12: 833773, 2022.

Article en En | MEDLINE | ID: mdl-36324594

Palabras clave

EGFR; cost-effectiveness; non-small-cell lung cancer; osimertinib; platinum-pemetrexed

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google